On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced that it had approved Opdivo (nivolumab) for the treatment of patients with...
A groundbreaking collaborative approach to
Introducing the Lung Cancer Master Protocol (Lung-MAP), a first-of-its-kind clinical trial that uses a multi-drug, targeted screening method to match patients with studies of investigational new treatments.I am a patientI am a healthcare provider/researcher
How it works.
Genomic profile screening
Find a cancer center
The trial is open at a nework of cancer centers, community hospitals, academic medical centers, and physican cooperatives across the United States with operations being managed by SWOG Cancer Research within the National Cancer Institute's National Clinical Trials Network.
News & Media
Trial will Close One of Five Trial Sub-Studies: Other four sub-studies of targeted treatments for squamous cell lung cancer will continue to...